Tolerogenic Dendritic Cell Therapy for Rheumatoid Arthritis

Inclusion Criteria: * Diagnosis of rheumatoid arthritis (RA) according to the criteria which were valid at time of diagnosis (i.e. 1987 Rheumatoid Arthritis Classification or 2010 American College of Rheumatology/EULAR RA Classification Criteria) * Stable dose, for at least 12 weeks, of any combination of disease-modifying antirheumatic drugs and glucocorticoids (maximum of 7.5 mg per day), with exception of those drugs that are part of the exclusion criteria. * Disease in remission or in low disease activity for at least 12 weeks (disease activity score of 28 joints \< 3.2) * Able and willing to give informed consent and to comply with the study protocol Exclusion Criteria: * Intramuscular or intra-articular glucocorticoid injection during 12 weeks prior to inclusion * Use of JAK inhibitors * Active or chronic infection (except fungal nail infection) * Infection requiring hospitalization or IV antibiotics within 6 weeks of baseline * Immunization with live vaccine within 6 weeks of baseline * History of malignancy (except treated basal cell carcinoma of skin) * Use of other investigational medicinal products within 30 days prior to study entry * Major surgery within 8 weeks of baseline or planned within 12 weeks from baseline * Pregnancy, or women planning to become pregnant within the study period, or women who are breast feeding * Hb\<6 mmol/L; neutrophils\< 2.00 x10\^9/L; platelets \<150x10\^9/L; alanine aminotransferase or alkaline phosphatase\>2x upper limit of normal; renal insufficiency (clearance \< 60 ml/min) at screening visit * Poor venous access or medical condition precluding leukapheresis * Serious or unstable co-morbidity deemed unsuitable by PI, e.g. chronic obstructive pulmonary disease, cardiac failure * Individuals of child bearing potential unwilling to use adequate contraception for duration the of study